Lupin Pharmaceuticals Patent-Cliff Exposure & CMS Drug Spending Portfolio
Lupin Pharmaceuticals (Baltimore, MD): 35 reconciled FDA prescription therapies, $380.8M 2024 CMS Part D & Medicaid spend, and $7,217 CA SB 17 specialty launch WAC.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Headquarters / Cluster | Baltimore, MD |
| Reconciled FDA Portfolio Therapies | 35 |
| 2025 to 2030 Patent-Cliff Revenue Exposure | 0.0% |
| Primary Portfolio LOE Date | 2028-01-01 |
| 2024 CMS Total Public Spend | $380.8M |
| 2024 Medicare Part D Spend | $294.2M |
| 2024 Medicaid Spend | $86.6M |
| California HCAI SB 17 Filings | Specialty launch notice ($7,217 intro WAC) |